Novartis and Roche's big-selling eye drug Lucentis has its first biosimilar competitor in Europe, after the European Commission approved Samsung Bioepis' copycat drug Byooviz. Byooviz (ranibizumab ...

Lucentis was first approved for wet AMD by the FDA in 2006. Genentech is also developing DutaFabs – the next generation of bispecific antibodies designed for increased efficacy and durability ...

It cites an “anticompetitive agreement” in the market for Lucentis active ingredient, the anti-VEGF antibody ranibizumab. Specifically, the ACGM claims that the companies entered into a ...

Retinopathy of prematurity (ROP), a condition frequently seen in the premature infant, remains one of these challenges. Physiological stressors cause abnormal growth of retinal blood vessels and ...

Roper Technologies, Inc. designs and develops vertical software and technology enabled products in the United States, Canada, Europe, Asia, and internationally. It operates through three segments ...

– Susvimo can help people with diabetic retinopathy (DR) maintain their vision and prevent progression to blindness with only one treatment every nine months – – Susvimo’s innovative ...

"The day came when I got to take Jack home,” the actress recalled at a 2021 event for the Global Alliance to Prevent Prematurity and Stillbirth, “and the first years were filled with doctor's ...

"The day came when I got to take Jack home,” the actress recalled at a 2021 event for the Global Alliance to Prevent Prematurity and Stillbirth, “and the first years were filled with doctor's ...

12 The customised formulation of ranibizumab delivered by Susvimo is different from the ranibizumab intravitreal injection, a medicine marketed as Lucentis® (ranibizumab injection)*, which is approved ...

– Susvimo can help people with diabetic retinopathy (DR) maintain their vision and prevent progression to blindness with only one treatment every nine months – – Susvimo’s innovative technology via ...